Clinical Trials Logo

Clinical Trial Summary

This randomized clinical trial studies how well tremelimumab and durvalumab with or without radiation therapy works in treating patients with small cell lung cancer that has returned after a period of improvement. Monoclonal antibodies, such as tremelimumab and durvalumab, may limit the ability of tumor cells to grow and spread by enhancing immune function. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tremelimumab and durvalumab together with radiation therapy may lead to improved clinical benefit.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To assess the efficacy (progression free survival [PFS] and objective response rate [ORR]) of combined immune checkpoint inhibitor therapy as treatment for relapsed small-cell lung cancer (SCLC). SECONDARY OBJECTIVES: I. To assess the impact of antigen priming using radiation therapy (XRT) on the efficacy of immune checkpoint inhibitors. II. To determine immune related objective response rate. III. To estimate overall survival measured as time from randomization to death from any cause. TERTIARY OBJECTIVES: I. To characterize tumor infiltrating lymphocytes (TILs) and programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 (PD1) expression in paired tumor biopsies at baseline, end of cycle 2 and at the time of progression. II. To determine dynamic changes in cell free deoxyribonucleic acid (DNA) (cfDNA) and the immunophenotype of peripheral blood repertoire of circulating lymphocytes using multiparameter flow cytometry. III. To determine changes in circulating cytokine mediators of inflammation and immunity using Luminex assay. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive tremelimumab intravenously (IV) over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation. ARM II: Patients undergo radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I. After completion of study treatment, patients are followed up periodically. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02701400
Study type Interventional
Source Emory University
Contact
Status Completed
Phase Phase 2
Start date April 14, 2016
Completion date August 7, 2020

See also
  Status Clinical Trial Phase
Terminated NCT02351505 - Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2
Completed NCT01737502 - Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01638546 - Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Phase 2
Completed NCT00887159 - A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Phase 2
Completed NCT01533181 - Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2
Completed NCT00856037 - Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer Phase 1
Active, not recruiting NCT03728361 - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Phase 2
Completed NCT01876446 - Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2